RxDoctor Payments Data

Adrienne Blessing, MD

Family Medicine · The Woodlands, TXNPI 1093151920

Payments from drug & device makers

$7,468in general payments, 2019–2025

Across 515 payments — averaging $14.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Pfizer$809
  • Lilly USA, LLC$544
  • Abbott$401
  • AstraZeneca$346
  • plus $3K from 41 others

What the payments were for

  • Food & beverage$7,468100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,468 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$83,757
Medicare patients
245
Services billed
1,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide107$139,136
EliquisApixaban53$55,100
MounjaroTirzepatide42$50,347
JardianceEmpagliflozin35$47,754
JanuviaSitagliptin Phosphate18$21,963
XareltoRivaroxaban17$20,055
MyrbetriqMirabegron13$17,620
FarxigaDapagliflozin Propanediol15$17,377
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$16,072
PaxlovidNirmatrelvir/Ritonavir18$5,716
Celecoxib96$5,180
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$3,609
SymbicortBudesonide/Formoterol Fumarate14$3,329
Levothyroxine Sodium315$2,916
SynthroidLevothyroxine Sodium47$2,910

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,092$139,136107 claims
PfizerEliquis, Paxlovid$809$60,81671 claims
Lilly USA, LLCMounjaro$544$50,34742 claims
Boehringer IngelheimJardiance$49$47,75435 claims
MerckJanuvia$28$21,96318 claims
AstraZenecaFarxiga, Symbicort$346$20,70629 claims
Astellas Pharma US IncMyrbetriq$281$17,62013 claims
GSKTrelegy Ellipta$333$16,07219 claims
AbbVieSynthroid$1,730$2,91047 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →